Last reviewed 2026-05-26 · How we verify

Vincamone (VINBURNINE)

Phase 2 active Small molecule ✓ Verified May 2026

Vincamone (generic name: VINBURNINE) is a vinburnine drug. It is currently in Phase 2 development.

Vincamone works by binding to the muscarinic acetylcholine receptor M3, which is involved in various physiological processes.

Vincamone is a small molecule with the synonyms including eburnamine, and it is also known as vinburnine.

Likelihood of approval

13.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Cardiovascular Phase 3 risk -2.0pp
Modern cardiovascular outcome trials are large + long; many fail to beat aggressive standard-of-care.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	VINBURNINE
Drug class	vinburnine
Target	Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M3
Modality	Small molecule
Therapeutic area	Cardiovascular
Phase	Phase 2

Mechanism of action

Imagine your body's nervous system as a complex network of messengers. Vincamone helps to block or modulate the activity of these messengers, specifically those that interact with the M3 receptor, which plays a role in various bodily functions such as heart rate and digestion.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Vincamone CI brief — competitive landscape report
Vincamone updates RSS · CI watch RSS

Frequently asked questions about Vincamone

What is Vincamone?

Vincamone (VINBURNINE) is a vinburnine drug.

How does Vincamone work?

Vincamone works by binding to the muscarinic acetylcholine receptor M3, which is involved in various physiological processes.

What is the generic name of Vincamone?

VINBURNINE is the generic (nonproprietary) name of Vincamone.

What drug class is Vincamone in?

Vincamone belongs to the vinburnine class. See all vinburnine drugs at /class/vinburnine.

What development phase is Vincamone in?

Vincamone is in Phase 2.

What does Vincamone target?

Vincamone targets Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M3 and is a vinburnine.

Drug class: All vinburnine drugs
Target: All drugs targeting Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M3
Therapeutic area: All drugs in Cardiovascular

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing